Janux Therapeutics (NASDAQ: JANX )’s know-how and scientific development have raised a lot of interest among investors, as well as numerous buy-out rumors. Although I would not discard the possibility of a buyout, I want to center my analysisOriginally a Biologist, M.Sc in Biomedicine, PhD in Bioengineering, with +20 years experience in the research and development of novel Cell & Gene Therapies (CGT) tackling several clinical needs. As an investor, I have been utilising my background in life sciences to as ...